

July 2022

Dear Optum 2022 HCPCS Level II Expert Customer:

The Centers for Medicare and Medicaid Services (CMS) has issued the following updates that can be marked in your book. Our customer service team is available to answer any questions at 1.800.464.3649, option 1.

Thank you for your patience and support of our ongoing efforts to deliver high-quality products. We value you as an Optum customer.

Sincerely,

Optum
www.optumcoding.com

The following codes are effective July 1, 2022:

New Code(s)

- A9596 Gallium Ga-68 gozetotide, diagnostic, (Illuccix), 1 mCi
- A9601 Flortaucipir F 18 injection, diagnostic, 1 mCi
- C9094 Injection, sutimlimab-jome, 10 mg
- C9095 Injection, tebentafusp-tebn, 1 mcg
- C9096 Injection, filgrastim-ayow, biosimilar, (Releuko), 1 mcg
- C9097 Injection, faricimab-svoa, 0.1 mg
- C9098 Ciltacabtagene autoleucel, up to 100 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- G0308 Creation of subcutaneous pocket with insertion of 180 day implantable interstitial glucose sensor, including system activation and patient training
- G0309 Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new 180 day implantable sensor, including system activation
- J0739 Injection, cabotegravir, 1 mg
- J1306 Injection, inclisiran, 1 mg

- J1551 Injection, immune globulin (Cutaquig), 100 mg
- J2356 Injection, tezepelumab-ekko, 1 mg
- J2779 Injection, ranibizumab, via intravitreal implant (Susvimo), 0.1 mg
- J2998 Injection, plasminogen, human-tvmh, 1 mg
- J3299 Injection, triamcinolone acetonide (Xipere), 1 mg
- J9331 Injection, sirolimus protein-bound particles, 1 mg
- J9332 Injection, efgartigimod alfa-fcab, 2 mg
- Q4259 Celera Dual Layer or Celera Dual Membrane, per sq cm
- Q4260 Signature APatch, per sq cm
- Q4261 TAG, per sq cm

Revised Code(s)

- A2004 XCelliStem, 1 mg

Deleted Code(s)

- C9090 Injection, plasminogen, human-tvmh, 1 mg
- C9091 Injection, sirolimus protein-bound particles, 1 mg
- C9092 Injection, triamcinolone acetonide, suprachoroidal (Xipere), 1 mg
- C9093 Injection, ranibizumab, via sustained release intravitreal implant (Susvimo), 0.1 mg
- G9678 Oncology Care Model (OCM) Monthly Enhanced Oncology Services (MEOS) payment for OCM-enhanced services. G9678 payments may only be made to OCM practitioners for OCM beneficiaries for the furnishment of enhanced services as defined in the OCM participation agreement